ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) has received regulatory approval for ANKTIVA® in Macau, marking its initial entry into the Asian market [1][2] - The approval is for the use of ANKTIVA in combination with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive non-muscle invasive bladder cancer [2] - The authorization was granted after a review of previous regulatory decisions by the U.S. FDA and the European Medicines Agency [2] Company Overview - ImmunityBio, Inc. is a clinical-stage immunotherapy company focused on developing next-generation therapies for cancer and infectious diseases [4] - The company's immunotherapy platform aims to activate both adaptive and innate immune systems to establish long-term immunological memory [4] Management Commentary - Patrick Soon-Shiong, M.D., emphasized that the approval in Macau underscores the robust clinical and regulatory foundation supporting ANKTIVA for BCG-unresponsive NMIBC CIS [3]